Drug Discovery
Our drug discovery platform is validated across hundreds of real-life projects and deployed broadly by the biopharma industry globally. The platform is also adopted by life science researchers worldwide to accelerate innovation in a range of applications such as food, fragrance, crop science, and more.
OUR COMPUTATIONAL PLATFORM ACCELERATES DRUG DISCOVERY
Platform differentiated by foundational scientific advances:
THE VALUE OF THE SCHRÖDINGER PLATFORM
Our computational platform gives you the tools to see familiar targets in new ways. Consider this case study, recently written up in Chemistry & Engineering News as part of an article on the allure of allosteric sites:
Medicinal chemists just couldn’t come up with a small molecule to potently block ACC’s shallow, hydrophobic active site....[But Nimbus Therapeutics] and Schrödinger, its computational partner, probed the interaction to generate virtual ACC inhibitors that Nimbus’s chemists eventually turned into a drug candidate. The discovery process took just 18 months, and the drug candidate, firsocostat, was so promising that, in 2016, Gilead Sciences paid $400 million to license it from Nimbus.
THE VALUE OF THE SCHRÖDINGER PLATFORM
We’re proud to partner with leading biotech and pharma companies around the world. In the spotlight this month: Morphic Therapeutic, a company we co-founded along with biochemist Timothy Springer and investors Polaris Partners and ShangPharma.
Morphic focuses on integrins -- receptors that lie at the heart of many cellular processes. The company recently signed high-profile research collaborations with AbbVie and Janssen Biotech. We’re delighted with these partnerships, which we hope will advance the drug discovery work we’ve done with Morphic into the clinic.